BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24242069)

  • 1. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.
    Watanabe T; Hotta C; Koizumi S; Miyashita K; Nakabayashi J; Kurotaki D; Sato GR; Yamamoto M; Nakazawa M; Fujita H; Sakai R; Fujisawa S; Nishiyama A; Ikezawa Z; Aihara M; Ishigatsubo Y; Tamura T
    Cancer Res; 2013 Nov; 73(22):6642-53. PubMed ID: 24242069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
    Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
    Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice.
    Casnici C; Volpe G; Crotta K; Lattuada D; Saglio G; Marelli O
    J Immunother; 2012 May; 35(4):321-8. PubMed ID: 22495389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.
    Inselmann S; Wang Y; Saussele S; Fritz L; Schütz C; Huber M; Liebler S; Ernst T; Cai D; Botschek S; Brendel C; Calogero RA; Pavlinic D; Benes V; Liu ET; Neubauer A; Hochhaus A; Burchert A
    Cancer Res; 2018 Nov; 78(21):6223-6234. PubMed ID: 30166420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small molecule significantly inhibits the bcr/abl fusion gene at the mRNA level in human chronic myelogenous leukemia.
    He Q; Dong J; Zhen H; Ying Y; Zhang J; Li Q; Li B; Zhou Y
    Leuk Res; 2011 Aug; 35(8):1074-9. PubMed ID: 21163528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells.
    Smit WM; Rijnbeek M; van Bergen CA; de Paus RA; Vervenne HA; van de Keur M; Willemze R; Falkenburg JH
    Hum Immunol; 1997 Apr; 53(2):216-23. PubMed ID: 9129981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Construction of genetically modified dendritic cell vaccine expressing bcr/abl fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in vitro].
    Wang WW; Huang RW; Hu Y; Li XD; Wang DN; He Y; Liu JJ
    Ai Zheng; 2009 Jun; 28(6):602-6. PubMed ID: 19635197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
    Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
    Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells.
    Mumprecht S; Claus C; Schürch C; Pavelic V; Matter MS; Ochsenbein AF
    Blood; 2009 May; 113(19):4681-9. PubMed ID: 19252140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model mice for BCR/ABL-positive leukemias.
    Honda H; Hirai H
    Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
    Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
    J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression/enhanced kinase activity of BCR/ABL and altered expression of Notch1 induced acute leukemia in p210BCR/ABL transgenic mice.
    Mizuno T; Yamasaki N; Miyazaki K; Tazaki T; Koller R; Oda H; Honda ZI; Ochi M; Wolff L; Honda H
    Oncogene; 2008 May; 27(24):3465-74. PubMed ID: 18193087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.